NSC 641396
NSC 641396 is a ribonucleotide reductase (RNR) inhibitor with an IC50 value of 1.2 μM. NSC 641396 is also a protein arginine N-methyltransferase 9 (PRMT9) inhibitor. NSC 641396 has antitumor activity.
For research use only. We do not sell to patients.
- CAS No.: 605685-94-7
- Formula: C18H13NO3
- Molecular Weight:291.30
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Chemical Information
-
CAS No. 605685-94-7
-
Molecular Weight 291.30
-
Formula C18H13NO3
-
SMILES
O=C1C=CC(C2=C1C=CC3=C2N(C)C4=CC=C(OC)C=C34)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
[1]. Tholander F, et al. Discovery of antimicrobial ribonucleotide reductase inhibitors by screening in microwell format. Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):9798-803. [Content Brief]
[2]. Dong H, et al. Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat Cancer. 2024 Apr;5(4):601-624. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NSC 641396 Related Classifications
HY-164497 Related Classifications
Powered by Bioz